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Abstract
Background: Nontuberculous mycobacterial (NTM) pulmonary disease has conventionally been classified on the
basis of radiology into fibrocavitary and nodular-bronchiectatic disease. Whilst being of great clinical utility, this may
not capture the full spectrum of radiological appearances present. The aim of this study was to use latent class
analysis (LCA) as an unbiased method of grouping subjects with NTM-pulmonary disease based on their CT features
and to compare the clinical characteristics of these groups.
Methods: Individuals with NTM-pulmonary disease were recruited and a contemporaneous CT scan obtained. This
was scored using an NTM-specific scoring system. LCA was used to identify groups with common radiological
characteristics. The analysis was then repeated in an independent cohort.
Results: Three classes were identified in the initial cohort of 85 subjects. Group 1 was characterised by severe
bronchiectasis, cavitation and aspergillomas, Group 2 by relatively minor radiological changes, and Group 3 by
predominantly bronchiectasis only. These findings were reproduced in an independent cohort of 62 subjects.
Subjects in Group 1 had a lower BMI and serum albumin, higher serum CRP, and a higher mortality.
Conclusions: These findings suggest that NTM-pulmonary may be divided into three radiological subgroups, and
that important clinical and survival differences exist between these groups.
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Background
Pulmonary non-tuberculous mycobacterial disease is a
challenging infection which is associated with a high
mortality [1–3]. Treatment is frequently poorly toler-
ated, expensive, and in many cases response rates are
poor [4]. Radiology is essential for the diagnosis of dis-
ease and has important implications in guiding treat-
ment. NTM-pulmonary disease has been observed to
commonly fall into two clinico-radiological patterns of
disease, fibrocavitary and nodular-bronchiectatic disease,
and this classification forms the basis of treatment rec-
ommendations in guidelines [5] and has important prog-
nostic implications [6–8]. Whilst being of great clinical
utility this division may not capture the spectrum of
radiological appearances, some of which may not fit
clearly into either group [3, 9–11].
The aim of this study was to characterise the radio-
logical features of NTM-pulmonary disease using an
NTM-specific scoring system, to use latent class analysis
(LCA) as an unbiased method to identify subgroups
sharing common patterns of radiological features, and to
examine the clinical characteristics associated with any
such patterns.
Methods
Individuals with NTM-pulmonary disease were recruited
prospectively from the outpatient department of the
Royal Brompton Hospital and Chelsea and Westminster
Hospital between September 2012 and November 2013.
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All met American Thoracic Society 2007 disease criteria
[5]. Subjects were excluded if they had a diagnosis of
cystic fibrosis, HIV infection or other primary or sec-
ondary immunodeficiency or if they were receiving any
immunosuppressant medication other than oral prednis-
olone. A HRCT scan of the thorax was performed in
subjects who had not undergone such a scan in the pre-
vious 6 months. In those who declined additional im-
aging as part of the study their most recent clinical
HRCT was obtained. Subjects also underwent a full clin-
ical assessment, blood and sputum sampling, St George’s
Respiratory Questionnaire (SGRQ) and lung function
testing. Written consent was gained from all participants
and the study was approved by the local Research Ethics
Committee (reference 12/LO/1034). Further details are
provided in the supplementary materials.
CT scoring was performed as previously described [12]
by a specialist radiologist with 5 years of experience in
thoracic imaging, blinded to clinical details. For bronchi-
ectasis extent, bronchiectasis severity, tree-in-bud opaci-
fication, nodules and consolidation, tertiles of the
maximum possible score for each feature were used to
categorise the features as low, medium or high. Cavitat-
ing nodules, severe cavitation and aspergilloma scores
were dichotomised as present or absent. As a measure of
the overall severity of an individual’s radiological disease
burden, composite CT scores were calculated for each
participant by expressing the individual scores for bron-
chiectasis extent, bronchiectasis severity, tree-in-bud
opacification, nodules, consolidation, cavitating nodules,
severe cavitation and aspergilloma as a percentage of the
maximum possible score for that feature, then summing
the scores together. The scoring proforma is detailed in
Additional file 1: Table S1 of the supplementary
material.
Statistical analysis was performed in the R environment
version 3.4.0 [13]. Latent class analysis (LCA) was per-
formed on the matrix of CT scores using the fpc and flex-
mix packages [14, 15]. LCA is a statistical method which
takes a set of multivariate data and uses this to identify
groups of related subjects (‘latent classes’) within the data
which share similar characteristics. The Aikake information
criteria (AIC) was used to identify the optimum number of
classes in the model as the number giving the lowest value
of AIC [16]. Composite CT scores were compared between
groups using analysis of variance (ANOVA). Clinical char-
acteristics were compared between groups using ANOVA,
Tukey’s Honestly Significant Difference test and Fisher’s
exact test. Survival curves were generated using the survival
package [17] and compared using the Log-rank test. Cor-
rection for multiple testing was performed using the
Benjamini-Hochberg method.
To examine the reproducibility of the groups identified
by LCA and their radiological characteristics, the analysis
was repeated on an independent cohort from another ter-
tiary centre. Subjects with NTM-pulmonary disease at
Papworth Hospital who underwent CT scanning at as part
of their clinical care were identified retrospectively, their
anonymised imaging and clinical data were retrieved and
data analysed using the exact methodology used for the
original cohort.
Results
A total of 85 subjects were recruited, their clinical and
radiological characteristics are shown in Additional file 1:
Tables S2 and S3 of the supplementary material. Twelve
subjects declined further imaging but had undergone
HRCT for clinical purposes which were obtained for ana-
lysis. The median interval between imaging and recruit-
ment was 23 days. In 80 (94%) subjects a HRCT was
obtained within twelve months of recruitment.
Identification of latent classes
Three latent classes were identified using the AIC (see
Additional file 1: Figure S1). There were 14 subjects
(16.4%) in class 1, 38 (44.7%) in class 2 and 33 (38.8%)
in class 3. The individual CT features of each of the la-
tent classes are shown in Fig. 1 and the total composite
CT scores in each class are shown in Fig. 2a.
The first class, referred to as “Cavitary” disease, was
characterised by the universal presence of severe cavita-
tion with medium or highly extensive bronchiectasis.
There was a high incidence of aspergilloma in this
group, seen in almost half, whereas they were almost ab-
sent from the other groups. The second class, referred
to as “Nodular” disease had the lowest composite CT
scores and a relative lack of radiological changes, with
the exception of nodules (medium levels in 13.5%) and
cavitating nodules which were present in 22.5%. The
third class, referred to as “Bronchiectatic” disease had
the most extensive bronchiectasis (high in 71.2%) which
was of high severity in the majority (56%), and the high-
est frequency of tree-in-bud changes (medium or high
levels in 28%), although cavitation and nodules were
uncommon.
The composite CT score (Fig. 2a) was highest in Cavi-
tary disease (mean 2.62), intermediate in Bronchiectatic
disease (mean 1.96) and lowest in Nodular disease
(0.95). All differences were significant at P < 0.001.
Clinical differences
The clinical characteristics of the latent classes are shown
in Table 1. Subjects from the Cavitary group were signifi-
cantly older than those in other classes (P = 0.003 vs Nodu-
lar, P = 0.079 vs Bronchiectatic groups). They had a higher
prevalence of semi-invasive aspergillosis, were more likely
to have received treatment for NTM and over one-third
were receiving systemic corticosteroids, although these
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differences were not significant. The mean C-reactive pro-
tein level was higher than both other classes (P < 0.001 vs
Nodular, P = 0.002 vs Bronchiectatic groups), body mass
index was lower (P = 0.003 vs Nodular, P = 0.008 vs Bronch-
iectatic groups) and serum albumin was lower than in the
Nodular (P = 0.007) but not the Bronchiectatic (P = 0.246)
group. The mean corrected carbon monoxide transfer
factor (TLCOc) was the lowest of the three groups,
but this did not reach significance. Dyspnoea and
quality of life scores were not significantly worse than
the other two classes.
Compared to the other groups, the Nodular group had
a more even mix of underlying respiratory pathology
and 21% had no underlying disease. Lung function indi-
ces were the highest of the three groups. This group had
the shortest mean duration of NTM disease prior to en-
rolment (P = 0.307 vs Cavitary, P = 0.008 vs Bronchiecta-
tic groups).
Fig. 1 CT features of latent classes identified in the Royal Brompton (left panel) and Papworth (right panel) cohorts. The three classes identified
by latent class analysis in each cohort are shown in the top, middle and bottom panels. The individual CT features used in the NTM scoring
system are shown on the x-axes and the proportion of subjects on the y-axes. Colours represent the severity (low, medium or high), or the
presence or absence of the CT feature
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Significantly more subjects (75.8%) in the Bronchiecta-
tic group had previously diagnosed underlying bronchi-
ectasis and 21.2% were chronically infected with
Pseudomonas, which was uncommon in the other
groups. The Bronchiectatic group had the highest rates
of antibiotic prophylaxis and the lowest rate of current
NTM treatment.
Survival data were available for 78 subjects with a me-
dian follow-up time of 126 weeks. There were significant
differences in survival seen between groups, with the
Cavitary group showing the highest mortality of 42.9%
compared with the bronchietatic (9.1%) and Nodular
(16.1%) groups (logrank test P = 0.011, Fig. 3).
Replication cohort
CT scans from 62 patients were available from Papworth
Hospital. Demographic details of the cohort are given in
Additional file 1: Table S4 of the supplementary material.
LCA identified three groups using the AIC (see Additional
file 1: Figure S1). Class 1 comprised 8 (12.9%) subjects,
class 2 comprised 19 (30.6%) subjects and class 3 com-
prised 35 (56.5%) subjects. The CT features of each class
showed high similarity to the Brompton cohort (Fig. 1).
Class 1 corresponded to the Cavitary group with uni-
versally severe bronchiectasis which was highly extensive
in 74.6%. Aspergillomas were present in 35.7% and the
majority had severe cavitation (71.9%) although this was
less than the universal presence seen in the Brompton
cohort. Another point of difference was the high level of
severe tree-in-bud change, seen in 87% but not seen in
the Brompton cohort. Class 2 corresponded to the
Nodular group, with generally mild changes except cavi-
tating nodules which were present in 14.9% and severe
cavitation in 20%. In contrast to the Brompton cohort,
aspergillomas were present in 10% and a medium level
of tree-in-bud changes in 40.2%. Class 3 corresponded
to the Bronchiectatic group with all subjects having high
severity bronchiectasis and 87.3% having highly exten-
sive bronchiectasis. In contrast to the Brompton cohort
the majority (90.5%) had a medium or high degree of
tree-in-bud changes and no subjects had medium or
high nodule scores compared with 12% in the Brompton
cohort. Similarly, the vast majority had no cavitating
nodules or severe cavitation, and aspergillomas were not
seen. As with the Brompton cohort, class 1 showed the
highest composite CT scores (mean 3.95), class 2 the
lowest (mean 0.97) and class 3 intermediate values
(mean 1.99). All differences were significant with P <
0.001 (Fig. 2b).
The mean age was youngest in class 2 and highest in
the class 1, although this difference was not significant.
There was significantly more underlying bronchiectasis
in class 3. There was significantly more MAC (87.5%) in
class 1 compared to other classes, whereas in the corre-
sponding Cavitary group from the Brompton cohort this
species accounted for only 50% of subjects.
Subgroup analysis of subjects with bronchiectasis
A subgroup analysis was performed restricted to subjects
with an underlying diagnosis of bronchiectasis. In the
Fig. 2 Composite CT scores between latent classes in the a) Royal Brompton and b) Papworth cohorts. The three classes identified by latent class
analysis in each cohort are shown on the x-axes, the composite CT score for each class are shown on the y-axis
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Table 1 Clinical characteristics of latent classes in the Royal Brompton cohort
Class P value Adjusted
P value1 2 3
N = 14 N = 38 N = 33
Female Sex 9 (64.3%) 22 (57.9%) 23 (69.7%) 0.571 0.670
Age (years) 72.4 (±10.0) 61.5 (±11.1) 66.8 (±9.1) 0.003 0.037
Smoking 0.411 0.575
Never smoker 6 (42.9%) 18 (47.4%) 17 (51.5%)
Ex-smoker 5 (35.7%) 16 (42.1%) 15 (45.5%)
Current smoker 3 (21.4%) 4 (10.5%) 1 (3.0%)
White - British Ethnicity 12 (85.7%) 30 (78.9%) 28 (84.8%) 0.747 0.747
Diagnosis 0.006 0.039
Bronchiectasis 5 (35.7%) 13 (34.2%) 25 (75.8%)
COPD 5 (35.7%) 11 (28.9%) 4 (12.1%)
Other 0 (0.0%) 6 (15.8%) 2 (6.1%)
No underlying disease 4 (28.6%) 8 (21.1%) 2 (6.1%)
Systemic corticosteroids 4 (28.6%) 7 (18.4%) 5 (15.2%) 0.574 0.670
Oral antibiotic prophylaxis 2 (14.3%) 9 (23.7%) 11 (33.3%) 0.404 0.575
Nebulised antibiotic prophylaxis 1 (7.1%) 2 (5.3%) 4 (12.1%) 0.677 0.702
Chronic Pseudomonas infection 0 (0.0%) 3 (7.9%) 7 (21.2%) 0.088 0.176
Semi-invasive Aspergillosis 2 (14.3%) 1 (2.6%) 0 0.069 0.155
NTM species 0.612 0.685
M. abscessus 4 (28.6%) 4 (10.5%) 6 (18.2%)
M. avium complex 7 (50.0%) 18 (47.4%) 19 (57.6%)
M. kansasii 1 (7.1%) 4 (10.5%) 4 (12.1%)
M. xenopi 1 (7.1%) 8 (21.1%) 2 (6.1%)
Other species 1 (7.1%) 4 (10.5%) 2 (6.1%)
Sputum smear positive 1 (7.1%) 3 (7.9%) 5 (15.2%) 0.639 0.688
Currently receiving NTM treatment 6 (42.9%) 8 (21.1%) 4 (12.1%) 0.072 0.155
Ever received NTM treatment 11 (78.6%) 15 (39.5%) 11 (33.3%) 0.015 0.060
Duration of NTM disease (years) 3.4 (±3.2) 1.6 (±2.6) 4.3 (±4.7) 0.01 0.047
Age at diagnosis (years) 69.6 (±9.9) 60.0 (±11.5) 62.5 (±10.6) 0.035 0.098
BMI (kg/m2) 18.3 (±3.2) 22.6 (±4.3) 22.3 (±3.4) 0.004 0.037
SGRQ total score 51.3 (±24.6) 42.1 (±26.1) 48.1 (±21.6) 0.443 0.591
MRC dyspnoea score 2.9 (±1.4) 2.4 (±1.5) 2.6 (±1.1) 0.513 0.653
FEV1 (% predicted) 58.7 (±13.3) 69.5 (±27.6) 53.9 (±20.1) 0.024 0.081
FVC (% predicted) 83.1 (±27.0) 97.7 (±20.8) 85.8 (±16.8) 0.026 0.081
TLCOc (% predicted) 47.9 (±24.1) 62.2 (±26.0) 59.2 (±18.2) 0.25 0.389
Haemoglobin (g/dL) 12.7 (±1.7) 13.7 (±1.6) 13.7 (±1.1) 0.049 0.125
Neutrophil count (× 109/L) 7.0 (±2.9) 5.3 (±3.0) 6.1 (±3.1) 0.186 0.326
Lymphocyte count (× 109/L) 1.4 (±0.5) 1.6 (±0.6) 1.8 (±0.7) 0.242 0.389
Serum albumin (g/L) 36.0 (±6.3) 40.2 (±3.7) 38.2 (±3.9) 0.007 0.039
CRP (mg/L) 37.2 (±51.1) 7.1 (±13.7) 10.0 (±13.5) < 0.001 0.017
Platelet count (× 109/L) 298 (±126) 244 (±62) 255 (±86) 0.126 0.235
Continuous variables are given as mean ± standard deviation and compared using ANOVA, categorical values are given as number and percentage and
compared using Fisher’s exact test
COPD chronic obstructive pulmonary disease, BMI body mass index, SGRQ St George’s Respiratory Questionnaire, MRC Medical Research Council
dyspnoea scale, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, TLCOc corrected transfer factor for carbon monoxide, CRP
C-reactive protein
Values shown in bold indicate P < 0.05
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Brompton cohort (N = 43), two classes were identified by
LCA representing 58 and 42% of the group (Additional
file 1: Fig. S2). The first class was characterised by bron-
chiectasis of predominantly low severity and an absence
of consolidation, severe cavitation or aspergillomas. It
contained all 13 subjects in the Nodular subgroup of
the full analysis, none from the Cavitary subgroup,
and 12 subjects from the Bronchiectatic subgroup
(see Additional file 1: Table S5 of the supplementary
material). The second class was characterised by exten-
sive and severe bronchiectasis, with severe cavitation in
30% and aspergillomas in 24%. This class contained all 5
subjects from the Cavitary subgroup of the full analysis,
no subjects from the Nodular subgroup and 13 subjects
from the Bronchiectatic subgroup.
In the Papworth cohort (N = 45) three classes were
identified representing 62, 21 and 16% of the group. The
features of these groups (Additional file 1: Fig. S3)
closely resembled those found in the larger cohort
(Fig. 1), corresponding to the ‘Bronchiectatic’, ‘Nodular’
and ‘Cavitary’ subgroups respectively. When compared
with the original classification, 96% of subjects remained
in the same subgroup (see Additional file 1: Table S5 of
the supplementary material).
Discussion
In this study, LCA identified three groups with distinct
radiological characteristics in two independent cohorts of
subjects with NTM-pulmonary disease. The finding of
compatible radiological changes is a cornerstone of the
diagnosis of NTM-pulmonary disease [5]. Historically the
radiological pattern associated with NTM-pulmonary dis-
ease was one of cavitation similar to tuberculosis, typically
seen in older males with underlying lung disease such as
emphysema [18]. In the later twentieth century the first
reports were published of a pattern of disease charac-
terised by nodules and bronchiectasis which in contrast
occurred in those with no underlying lung disease and
was more common in women [19, 20]. The differentiation
between the former ‘fibrocavitary’ disease and latter
‘nodular-bronchiectatic’ disease is of major clinical im-
portance, as several studies have consistently demon-
strated an association between fibrocavitary disease and
mortality [6–8], disease progression [7] and treatment fail-
ure [21, 22]. This has been reflected in successive guide-
lines which recommend more aggressive treatment of
fibrocavitary disease [5]. Other patterns of disease have
been reported, in particular consolidation and infiltrative
patterns have been associated with poor outcomes [9–11]
however with no agreed consensus regarding definitions
for these patterns, the findings remain unique to the indi-
vidual studies. Even when an additional ‘consolidative’
category was used, one study found that 27% of subjects
still did not clearly fit any category [3] and another was
still unable to classify the radiological appearances of
229/481 subjects [9].
Our current study used a predefined scoring system to
reduce subjectivity in assessing NTM related radiological
changes, and latent class analysis as an unbiased method
to identify groups sharing radiological characteristic
without presupposing the existence of any specific pat-
terns of disease.
The findings support the existence of fibrocavitary
disease as a distinct pattern, identifying a group char-
acterised by severe cavitation associated with markers
of disease severity and a high mortality. There was a
Fig. 3 Kaplan-Meier survival curves for latent classes in the Royal Brompton cohort. X-axis = time (weeks), Y-axis = Proportion surviving,
lines = latent classes
Cowman et al. BMC Pulmonary Medicine  (2018) 18:145 Page 6 of 8
high prevalence of aspergilloma within this group,
which has been associated with increased mortality in
NTM-pulmonary disease [12].
Within the remaining majority of subjects, LCA iden-
tified two distinct subgroups, split evenly into those with
very few radiological changes apart from nodules, and
those with marked bronchiectasis. As may be expected,
significantly more subjects in the latter Bronchiectatic
group has pre-existing bronchiectasis, although this was
also the case in over a third of those with ‘nodular’ dis-
ease. Interestingly despite having the best-preserved lung
function and lowest symptom scores, there was no sig-
nificant difference in mortality between the nodular and
bronchiectatic groups. The duration of disease was sig-
nificantly shorter in the nodular group, raising the possi-
bility that this represents early disease which may
progress to Cavitary or Bronchiectatic forms. A pattern
of nodules and bronchiectasis have been associated with
M. avium complex infection in a single study [23] how-
ever there were no differences in species prevalence be-
tween groups.
The validation cohort confirms the presence of three
subgroups whose radiological characteristics shared
many similarities with the Brompton cohort. There was
a smaller group characterised by high composite CT
scores with severe cavitation, the common presence of
aspergillomas and severe and extensive bronchiectasis,
corresponding to the Cavitary group. The other subjects
were divided into those dominated by severe and exten-
sive bronchiectasis without nodules, cavitation or asper-
gilloma (corresponding to the Bronchiectatic group) and
those with low composite CT scores and low scores for
most CT features (corresponding to the Nodular group).
A higher proportion of subjects fell into the Bronchiec-
tatic group, likely due to the higher overall prevalence of
underlying bronchiectasis in this cohort.
The only major difference to the Brompton cohort
was the higher prevalence of tree-in-bud changes, which
were moderate or severe in 76% compared with 17%.
The prevalence was higher in all three disease subgroups
and does not appear to be due to the increased preva-
lence of underlying bronchiectasis. As the scoring of the
validation cohort was performed separately to the
Brompton cohort observer bias may be responsible for
this difference, although this was performed by the same
individual, alternatively it may be that differences in
treatment, coinfection, or other clinical factors between
centres is responsible. There was also more severe cavi-
tation and aspergilloma in the nodular Papworth group
compared with the Brompton, however only four sub-
jects accounted for this difference.
In contrast to other studies mentioned previously,
the presence of a separate consolidative pattern of
NTM-pulmonary disease was not seen in this study.
The vast majority of subjects in both cohorts had only
mild consolidation, although this feature was slightly
more prominent in the Cavitary group. Only one sub-
ject had consolidation and no other feature of NTM
disease. Our findings may in part be explained by the
absence of immunocompromised or critically ill subjects
from our cohorts. When the analysis was restricted to
subjects with known underlying bronchiectasis only two
subgroups were identified, with the Bronchiectatic group
being split in half dividing the cohort into groups more
consistent with the conventional ‘fibrocavitary’ and ‘nodu-
lar-bronchiectatic’ patterns. However, in the validation
cohort the three subgroups were still clearly identified.
The principle limitation of the study is the heteroge-
neous nature of the cohort, comprising subjects with dif-
fering underlying respiratory diseases, NTM species,
antibiotic treatments and infecting co-pathogens. Never-
theless the findings were replicable in an independent
cohort suggesting they are not merely related to the spe-
cific case mix at a single centre. Furthermore, such a
mix of subjects is representative of real-life clinical prac-
tice, although as both cohorts come from tertiary centres
the proportion of subjects with severe bronchiectasis
and aspergillomas may be higher than the wider popula-
tion of individuals with NTM-pulmonary disease. A
number of subjects had previously undergone HRCT
and declined further imaging, therefore in some subjects
the collected clinical data may not reflect the point in
time when the HRCT was performed and in 10% of
cases more than a year had elapsed from imaging to
study enrolment. A single radiologist was responsible for
performing CT scoring and despite the use of an object-
ive scoring system this remains a potential source of
bias, although the scoring system was based on the
Bhalla score [24] which has been shown to have low in-
terobserver variability [25].
Conclusions
This study provides validation of the existence of cavi-
tary disease as a distinct phenotype of NTM-pulmonary
disease associated with a poor prognosis. In addition
they suggest that ‘nodular-bronchiectatic’ disease is
formed of two separate groups with important radio-
logical and clinical differences, which may possibly re-
flect differences in underlying lung disease or duration
of infection. These data underline that fact that
NTM-pulmonary disease is a heterogeneous condition
and more precise phenotyping will be valuable in clinical
decision making and stratification in clinical trials.
Additional file
Additional file 1: Supplementary materials. (DOCX 1280 kb)
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